Ernesto Perez-Mejias

Madrid, MD, Spain

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 13 publications

The Envelope-Based Fusion Antigen GP120C14K Forming Hexamer-Like Structures Triggers T Cell and Neutralizing Antibody Responses Against HIV-1.

The Envelope-Based Fusion Antigen GP120C14K Forming Hexamer-Like Structures Triggers T Cell and Neutralizing Antibody Responses Against HIV-1.

Journal: Frontiers in immunology

Published: May 30, 2019

Development of a Safe and Effective Vaccinia Virus Oncolytic Vector WR-Δ4 with a Set of Gene Deletions on Several Viral Pathways.

Development of a Safe and Effective Vaccinia Virus Oncolytic Vector WR-Δ4 with a Set of Gene Deletions on Several Viral Pathways.

Journal: Molecular therapy oncolytics

Published: December 01, 2017

Distinct Roles of Vaccinia Virus NF-κB Inhibitor Proteins A52, B15, and K7 in the Immune Response.

Distinct Roles of Vaccinia Virus NF-κB Inhibitor Proteins A52, B15, and K7 in the Immune Response.

Journal: Journal of virology

Published: April 04, 2017

A Prime/Boost PfCS14KM/MVA-sPfCSM Vaccination Protocol Generates Robust CD8+ T Cell and Antibody Responses to Plasmodium falciparum Circumsporozoite Protein and Protects Mice against Malaria.

A Prime/Boost PfCS14KM/MVA-sPfCSM Vaccination Protocol Generates Robust CD8+ T Cell and Antibody Responses to Plasmodium falciparum Circumsporozoite Protein and Protects Mice against Malaria.

Journal: Clinical and vaccine immunology : CVI

Published: October 18, 2016

Enhanced anti-tumour immunity requires the interplay between resident and circulating memory CD8+ T cells.

Enhanced anti-tumour immunity requires the interplay between resident and circulating memory CD8+ T cells.

Journal: Nature communications

Published: October 11, 2016

NYVAC vector modified by C7L viral gene insertion improves T cell immune responses and effectiveness against leishmaniasis.

NYVAC vector modified by C7L viral gene insertion improves T cell immune responses and effectiveness against leishmaniasis.

Journal: Virus research

Published: February 18, 2016

Modification of promoter spacer length in vaccinia virus as a strategy to control the antigen expression.

Modification of promoter spacer length in vaccinia virus as a strategy to control the antigen expression.

Journal: The Journal of general virology

Published: May 15, 2015

NFκB activation by modified vaccinia virus as a novel strategy to enhance neutrophil migration and HIV-specific T-cell responses.

NFκB activation by modified vaccinia virus as a novel strategy to enhance neutrophil migration and HIV-specific T-cell responses.

Journal: Proceedings of the National Academy of Sciences of the United States of America

Published: March 06, 2015

The evolution of poxvirus vaccines.

The evolution of poxvirus vaccines.

Journal: Viruses

Published: January 30, 2015

Virological and immunological characterization of novel NYVAC-based HIV/AIDS vaccine candidates expressing clade C trimeric soluble gp140(ZM96) and Gag(ZM96)-Pol-Nef(CN54) as virus-like particles.

Virological and immunological characterization of novel NYVAC-based HIV/AIDS vaccine candidates expressing clade C trimeric soluble gp140(ZM96) and Gag(ZM96)-Pol-Nef(CN54) as virus-like particles.

Journal: Journal of virology

Published: October 31, 2014

New vaccinia virus promoter as a potential candidate for future vaccines.

New vaccinia virus promoter as a potential candidate for future vaccines.

Journal: The Journal of general virology

Published: October 01, 2013

Attenuated and replication-competent vaccinia virus strains M65 and M101 with distinct biology and immunogenicity as potential vaccine candidates against pathogens.

Attenuated and replication-competent vaccinia virus strains M65 and M101 with distinct biology and immunogenicity as potential vaccine candidates against pathogens.

Journal: Journal of virology

Published: April 19, 2013

Showing 1-12 of 13

Last Updated: 09/26/2026